Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

Decorin protein in blood inhibits tumor progression, say researchers

Researchers from Thomas Jefferson University's Kimmel Cancer Center have discovered that decorin, a naturally occurring protein that circulates in the blood, acts as a potent inhibitor of tumor growth modulating the tumor microenvironment.

28 Jun 2013

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened enrollment in a Phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies.

26 Jun 2013

NUS researchers develop highly realistic 3-D tumor model to track progress of drug therapy

A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3-D) tumour model. As it replicates the conditions in the body, it is able to track the effectiveness and progress of drug therapy.

20 Jun 2013

Researchers develop method to identify aggressive prostate cancers

Researchers at Moffitt Cancer Center and colleagues at Louisiana State University have developed a method for identifying aggressive prostate cancers that require immediate therapy. It relies on understanding the genetic interaction between single nucleotide polymorphisms. The goal is to better predict a prostate cancer's aggressiveness to avoid unnecessary radical treatment.

20 Jun 2013

Nation's leading experts join forces to accelerate effective treatments for brain tumors

The nation's leading brain tumor and biotech industry experts again joined forces Friday, June 7, in a bid to accelerate more effective treatments for brain tumors and promote funding for the latest emerging therapies, as the Weill Cornell Brain and Spine Center and Voices Against Brain Cancer hosted its second annual Brain Tumor Biotech Summit.

10 Jun 2013

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase 2 trial for BL-8040, for the treatment of acute myeloid leukemia.

6 Jun 2013

Researchers demonstrate how modified citrus pectin works against cancer

A new review by researchers at the University of Maryland School of Medicine highlights a large body of published research demonstrating how modified citrus pectin, works against cancer.

4 Jun 2013

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.

3 Jun 2013

Study investigates gene expression signature to predict response to bevacizumab

A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin-), according to new research from The University of Texas MD Anderson Cancer Center.

3 Jun 2013

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.

31 May 2013

EGFR gums up cell's miRNA-processing machinery under oxygen starvation conditions

Even while being dragged to its destruction inside a cell, a cancer-promoting growth factor receptor fires away, sending signals that thwart the development of tumor-suppressing microRNAs before it's dissolved, researchers reported in an early online publication at Nature.

24 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.

15 May 2013

Research on total anomalous pulmonary venous connection

Total anomalous pulmonary venous connection, one type of "blue baby" syndrome, is a potentially deadly congenital disorder that occurs when pulmonary veins don't connect normally to the left atrium of the heart.

13 May 2013

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol.

3 May 2013

Researchers find that VEGF may not have any prognostic value for advanced prostate cancer

The well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers from the Department of Radiation Oncology at Thomas Jefferson University Hospital and other institutions found in a retrospective study published online April 25 in the journal BMC Radiation Oncology.

30 Apr 2013

Study confirms that mesenchymal stem cells may help treat cancer

Injection of human stem cells into mice with tumors slowed down tumor growth, finds research published in BioMed Central's open access journal Stem Cell Research & Therapy.

29 Apr 2013

Ampio completes patient enrollment in dose-escalation run-in study of Ampion for treatment of knee osteoarthritis

Ampio Pharmaceuticals, Inc. today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe osteoarthritis of the knee.

26 Apr 2013

Stem cell transplant regimen to treat neuroblastoma in children appears to be more toxic in US

The stem cell transplant regimen that was commonly used in the United States to treat advanced neuroblastoma in children appears to be more toxic than the equally effective regimen employed in Europe and Egypt, according to a new study to be presented at the 26th annual meeting of the American Society of Pediatric Hematology Oncology in Miami April 24-27.

25 Apr 2013

Study: Nearly two-thirds of children receiving stem cell transplants return to hospital within six months

Nearly two-thirds of children receiving stem cell transplants returned to the hospital within six months for treatment of unexplained fevers, infections or other problems, according to a study performed at Dana-Farber/Children's Hospital Cancer Center in Boston.

24 Apr 2013